Literature DB >> 27777141

Angiogenic Factors Correlate with T Cell Immune Reconstitution and Clinical Outcomes after Double-Unit Umbilical Cord Blood Transplantation in Adults.

Ioannis Politikos1, Haesook T Kim2, Theodoros Karantanos1, Julia Brown1, Sean McDonough3, Lequn Li1, Corey Cutler3, Joseph H Antin3, Karen K Ballen4, Jerome Ritz3, Vassiliki A Boussiotis5.   

Abstract

Umbilical cord blood (UCB) is a valuable graft source for allogeneic hematopoietic stem cell transplantation (HSCT) in patients who lack adult donors. UCB transplantation (UCBT) in adults results in delayed immune reconstitution, leading to high infection-related morbidity and mortality. Angiogenic factors and markers of endothelial dysfunction have biologic and prognostic significance in conventional HSCT, but their role in UCBT has not been investigated. Furthermore, the interplay between angiogenesis and immune reconstitution has not been studied. Here we examined whether angiogenic cytokines, angiopoietin-1 (ANG-1) and vascular endothelial growth factor (VEGF), or markers of endothelial injury, thrombomodulin (TM) and angiopoietin-2 (ANG-2), associate with thymic regeneration as determined by T cell receptor excision circle (TREC) values and recovery of T cell subsets, as well as clinical outcomes in adult recipients of UCBT. We found that plasma levels of ANG-1 significantly correlated with the reconstitution of naive CD4+CD45RA+ and CD8+CD45RA+ T cell subsets, whereas plasma levels of VEGF displayed a positive correlation with CD4+CD45RO+ T cells and regulatory T cells and a weak correlation with TRECs. Assessment of TM and ANG-2 revealed a strong inverse correlation of both factors with naive T cells and TRECs. The angiogenic capacity of each patient's plasma, as determined by an in vitro angiogenesis assay, positively correlated with VEGF levels and with reconstitution of CD4+ T cell subsets. Higher VEGF levels were associated with worse progression-free survival and higher risk of relapse, whereas higher levels of TM were associated with chronic graft-versus-host disease and nonrelapse mortality. Thus, angiogenic factors may serve as valuable markers associated with T cell reconstitution and clinical outcomes after UCBT.
Copyright © 2017 The American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ANG-1; ANG-2; Angiogenic factors; Immune reconstitution; TM; Umbilical cord blood transplantation; VEGF

Mesh:

Substances:

Year:  2016        PMID: 27777141      PMCID: PMC5489056          DOI: 10.1016/j.bbmt.2016.10.013

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  65 in total

1.  Vascular endothelial growth factor (VEGF) is associated with reduced severity of acute graft-versus-host disease and nonrelapse mortality after allogeneic stem cell transplantation.

Authors:  C-K Min; S Y Kim; M J Lee; K S Eom; Y J Kim; H J Kim; S Lee; S G Cho; D W Kim; J W Lee; W S Min; C C Kim; C S Cho
Journal:  Bone Marrow Transplant       Date:  2006-06-05       Impact factor: 5.483

2.  Increased plasma level of vascular endothelial glycoprotein thrombomodulin as an early indicator of endothelial damage in bone marrow transplantation.

Authors:  S Testa; A Manna; A Porcellini; F Maffi; G Morstabilini; N Denti; S Macchi; G Rosti; G Porcellini; D Cassi; L Ferrari
Journal:  Bone Marrow Transplant       Date:  1996-08       Impact factor: 5.483

3.  Cytokine profiles in stem cell transplantation: possible use as a predictor of graft-versus-host disease.

Authors:  R A Lunn; N Sumar; A S Bansal; J Treleaven
Journal:  Hematology       Date:  2005-04       Impact factor: 2.269

4.  Endothelial cell markers in bone marrow transplant recipients with and without acute graft-versus-host disease.

Authors:  C Salat; E Holler; H J Kolb; R Pihusch; B Reinhardt; E Hiller
Journal:  Bone Marrow Transplant       Date:  1997-05       Impact factor: 5.483

5.  Expression of VEGF and its receptors by myeloma cells.

Authors:  S Kumar; T E Witzig; M Timm; J Haug; L Wellik; R Fonseca; P R Greipp; S V Rajkumar
Journal:  Leukemia       Date:  2003-10       Impact factor: 11.528

6.  Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice.

Authors:  F Shalaby; J Rossant; T P Yamaguchi; M Gertsenstein; X F Wu; M L Breitman; A C Schuh
Journal:  Nature       Date:  1995-07-06       Impact factor: 49.962

7.  Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma.

Authors:  Abby B Siegel; Emil I Cohen; Allyson Ocean; Deborah Lehrer; Alec Goldenberg; Jennifer J Knox; Helen Chen; Sean Clark-Garvey; Alan Weinberg; John Mandeli; Paul Christos; Madhu Mazumdar; Elizabeta Popa; Robert S Brown; Shahin Rafii; Jonathan D Schwartz
Journal:  J Clin Oncol       Date:  2008-06-20       Impact factor: 44.544

8.  Changes in thymic function with age and during the treatment of HIV infection.

Authors:  D C Douek; R D McFarland; P H Keiser; E A Gage; J M Massey; B F Haynes; M A Polis; A T Haase; M B Feinberg; J L Sullivan; B D Jamieson; J A Zack; L J Picker; R A Koup
Journal:  Nature       Date:  1998-12-17       Impact factor: 49.962

9.  Level of vascular endothelial growth factor predicts both relapse and nonrelapse mortality after allogeneic hematopoietic stem cell transplantation.

Authors:  Ivan S Moiseev; Sergey V Lapin; Elena A Surkova; Margarita Y Lerner; Vladimir N Vavilov; Boris V Afanasyev
Journal:  Biol Blood Marrow Transplant       Date:  2013-09-10       Impact factor: 5.742

10.  Clearance of CMV viremia and survival after double umbilical cord blood transplantation in adults depends on reconstitution of thymopoiesis.

Authors:  Julia A Brown; Kristen Stevenson; Haesook T Kim; Corey Cutler; Karen Ballen; Sean McDonough; Carol Reynolds; Maria Herrera; Deborah Liney; Vincent Ho; Grace Kao; Philippe Armand; John Koreth; Edwin Alyea; Steve McAfee; Eyal Attar; Bimalangshu Dey; Thomas Spitzer; Robert Soiffer; Jerome Ritz; Joseph H Antin; Vassiliki A Boussiotis
Journal:  Blood       Date:  2010-01-27       Impact factor: 22.113

View more
  3 in total

1.  Favorable outcomes of COVID-19 in recipients of hematopoietic cell transplantation.

Authors:  Gunjan L Shah; Susan DeWolf; Yeon Joo Lee; Roni Tamari; Parastoo B Dahi; Jessica A Lavery; Josel Ruiz; Sean M Devlin; Christina Cho; Jonathan U Peled; Ioannis Politikos; Michael Scordo; N Esther Babady; Tania Jain; Santosha Vardhana; Anthony Daniyan; Craig S Sauter; Juliet N Barker; Sergio A Giralt; Cheryl Goss; Peter Maslak; Tobias M Hohl; Mini Kamboj; Lakshmi Ramanathan; Marcel Rm van den Brink; Esperanza Papadopoulos; Genovefa Papanicolaou; Miguel-Angel Perales
Journal:  J Clin Invest       Date:  2020-12-01       Impact factor: 14.808

Review 2.  Regulatory T Cells in Angiogenesis.

Authors:  Zala Lužnik; Sonia Anchouche; Reza Dana; Jia Yin
Journal:  J Immunol       Date:  2020-11-15       Impact factor: 5.426

3.  Coordinated responses of natural anticoagulants to allogeneic stem cell transplantation and acute GVHD - A longitudinal study.

Authors:  Beata Przybyla; Anne Pinomäki; Jari Petäjä; Lotta Joutsi-Korhonen; Karin Strandberg; Andreas Hillarp; Ann-Kristin Öhlin; Tapani Ruutu; Liisa Volin; Riitta Lassila
Journal:  PLoS One       Date:  2017-12-22       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.